Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 10:14:1285901.
doi: 10.3389/fendo.2023.1285901. eCollection 2023.

Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives

Affiliations
Review

Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives

Anette S B Wolff et al. Front Endocrinol (Lausanne). .

Abstract

The adrenal glands are small endocrine glands located on top of each kidney, producing hormones regulating important functions in our body like metabolism and stress. There are several underlying causes for adrenal insufficiency, where an autoimmune attack by the immune system is the most common cause. A number of genes are known to confer early onset adrenal disease in monogenic inheritance patterns, usually genetic encoding enzymes of adrenal steroidogenesis. Autoimmune primary adrenal insufficiency is usually a polygenic disease where our information recently has increased due to genome association studies. In this review, we go through the physiology of the adrenals before explaining the different reasons for adrenal insufficiency with a particular focus on autoimmune primary adrenal insufficiency. We will give a clinical overview including diagnosis and current treatment, before giving an overview of the genetic causes including monogenetic reasons for adrenal insufficiency and the polygenic background and inheritance pattern in autoimmune adrenal insufficiency. We will then look at the autoimmune mechanisms underlying autoimmune adrenal insufficiency and how autoantibodies are important for diagnosis. We end with a discussion on how to move the field forward emphasizing on the clinical workup, early identification, and potential targeted treatment of autoimmune PAI.

Keywords: 21-hydroxylase autoantibodies; Addisons disease; Genetic causes of PAI; glucococorticoids; primary adrenal insufficiency (PAI).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Steroidogenesis pathway. The enzymes specified are encoded by the genes stated in parenthesis under respective enzymes. The genes that are not stated in parenthesis are represented with symbols. The enzymes in red are targets for autoantibodies in autoimmune primary adrenal insufficiency. Figure created in BioRender.com. Modified from (1).
Figure 2
Figure 2
Hypothalamic-pituitary-adrenal (HPA) axis. The outline of the HPA axis between the hypothalamus, pituitary gland and the adrenal cortex is shown, including the negative feedback-loop. CRH, corticotropin-releasing hormone; ACTH, adrenocorticotropic hormone. Figure created in BioRender.com.
Figure 3
Figure 3
PAI genetics. The most common monogenic genetic causes of PAI (green) and 8 genes/gene regions where specific variants cause extra risk for autoimmune PAI in a polygenic setting on a genome–wide basis (orange). Based on http://www.icped.org/, and (25, 26).
Figure 4
Figure 4
The natural cause of progression of autoimmune diseases. We are today posed to identify the genetic predisposition in AAD, and to provide replacement therapy in Stage 3, when overt disease is evident. Autoantibodies against 21OH can appear as early as in the pre-stage, as markers of the autoimmune reaction. Modified from (66) and created in BioRender.com.
Figure 5
Figure 5
Outlined screening possibilities for PAI. The figure suggests two different strategies for early identification of PAI. Population-based screening dependent on polygenic risk scores and genetic screening of risk variants (1) or 21-OH autoantibody measurements in high-risk groups either identified by genetic screens or family history (2). Figure created in BioRender.com.

References

    1. Hall JE. Guyton and hall textbook of medical physiology. Amsterdam, The Netherlands: Elsevier; (2020).
    1. Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. . Adrenal insufficiency. Nat Rev Dis Primers (2021) 7:19. doi: 10.1038/s41572-021-00252-7 - DOI - PubMed
    1. Erichsen MM, Lovas K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, et al. . Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab (2009) 94:4882–90. doi: 10.1210/jc.2009-1368 - DOI - PubMed
    1. Meyer G, Badenhoop K, Linder R. Addison's disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin Endocrinol (Oxf) (2016) 85:347–53. doi: 10.1111/cen.13043 - DOI - PubMed
    1. Olafsson AS, Sigurjonsdottir HA. Increasing prevalence of addison disease: results from a nationwide study. Endocr Pract (2016) 22:30–5. doi: 10.4158/EP15754.OR - DOI - PubMed

Publication types